eGFR, estimated glomerular filtration rate

eGFR, estimated glomerular filtration rate. The first cohort (86 DSA+ recipients) Difluprednate was recruited post-transplant DSA screening for a randomized controlled interventional trial to evaluate the effect of the proteasome inhibitor bortezomib in late ABMR (BORTEJECT, ClinicalTrials.gov: “type”:”clinical-trial”,”attrs”:”text”:”NCT01873157″,”term_id”:”NCT01873157″NCT01873157) (24). and activating receptors, some of them interacting with HLA class I molecules as critical immune checkpoints (1). One activating receptor that could potentially contribute to NK cell-driven alloimmune injury, is the C-type lectin NKG2C (CD159c), a type II integral membrane protein encoded by the gene located in the Difluprednate NK complex on chromosome 12p13. NKG2C covalently assembles with CD94. The CD94/NKG2C heterodimers bind specifically to HLA-E molecules, which are stabilized by human or viral peptides on the surface of stressed or infected cells. Receptor binding triggers cytotoxic responses and the release of pro-inflammatory molecules, thus promoting the adaptive differentiation and growth of NKG2C+ NK cells (14). The conversation of CD94/NKG2C with HLA-E requires the binding of viral (e.g. CMV-derived) peptides or leader sequences of classical and non-classical HLA molecules. It was shown that the leader peptide of the non-classical HLA-G molecule VMAPRTLFL is usually a strong HLA-mediated activator of CD94/NKG2C mediated cytotoxicity and proliferation of NKG2C+ NK cells (15). In a recently published study, using a Puumala computer virus model, we could demonstrate, that this cellular stress responses and upregulation of HLA-G is indeed DPP4 sufficient to induce a potent HLA-E-mediated cytotoxic NKG2C+ NK cell response (16). The level of NKG2C expression may be determined by a distinct polymorphism leading to homo- (absent expression) or heterozygous (lower expression) deletion of the gene, which in different populations was found in up to 2% and 33% of tested individuals, respectively (17). This genetic variation has a strong impact on the number and functionality of NKG2C+ NK cells (18C20). Clinical association studies have suggested that NKG2C copy number is related to the susceptibility and/or severity of different viral infections, as has been shown for cytomegalovirus (CMV) in lung transplant recipients (21), HIV (22) and SARS-CoV-2 (17). There is some evidence that NKG2C+ NK cells contribute to transplant rejection, as has recently been shown for recipients of lung allografts (23). The role of NKG2C expression or gene variations in kidney transplantation, however, has not yet been investigated. Hypothesizing a role of NKG2C+ NK cells in the context of antibody-dependent and -impartial alloresponses, we sought to investigate whether and to which extent deletion of the gene protects allografts from DSA-triggered microcirculation injury. Moreover, we were interested, if there is any additive effect of a Difluprednate functional SNP in the FcRIIIA gene (variants in a large, randomly selected multicenter prospective cohort of 1 1,860 recipients of deceased donor kidney transplants. Materials and Methods Study Design and Patient Cohorts The study included two impartial prospective transplant cohorts, (i) a cohort of 86 kidney transplant recipients [BORTEJECT cohort (24)] who, based on a positive post-transplant DSA result, underwent allograft biopsies, and (ii) a large cohort of randomly selected recipient/donor pairs from the multicenter Collaborative Transplant Study (CTS, www.ctstransplant.org). A flow chart of the study is provided in Physique?1 . Genotyping and statistical data analysis were carried out in a retrospective and blinded fashion. Open in a separate window Physique?1 Study flow chart. Systematic cross-sectional antibody-mediated rejection (ABMR) Difluprednate screening of a cohort of 741 kidney transplant recipients (BORTEJECT trial) led to the identification of 111 donor-specific antibody (DSA)-positive recipients. Eighty-six DSA+ patients underwent protocol biopsies. For all those 86 subjects (primary study cohort) adequate material for genotyping was available. A control group of 106 recipients was defined by propensity score matching as described in the methods section. A large prospective multicenter cohort (Collaborative Transplant Study, CTS; 1,860 recipient/donor pairs) was included to assess associations of genotyping results in relation.